In-licensing
505(b)(2) formulation for the treatment of chemotherapy induced nausea and vomiting. Multiple advantages over currently available products including the ability to use without further reconstitution.
505(b)(2) formulation for schizophrenia available for in-licensing:
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space. US rights only.
505(b)(2) product for the treatment of schizophrenia available for in-licensing. Multiple markets available including the US. NDA filed in the US in 2019. Approval expected in 2021.